48 de publicații, 29 cu DOI verificabil

Dintre acestea, 29 sunt articole în reviste indexate, cu DOI verificabil. Restul sunt capitole de carte, postere și comunicări la conferințe naționale și internaționale. Sursă: CV profesional, actualizat august 2026.

1. 2026

   Body Mass Index and Outcomes in HR+/HER2− Metastatic Breast Cancer Treated with Palbociclib: Insights from a National Real-World Study

   Cancers · 2026 DOI ↗
2. 2026

   Giant Malignant Phyllodes Tumor with Secondary Thyroid Involvement

   Diseases · 2026 DOI ↗
3. 2026

   Romanian Consensus Statement for Hormone Receptor-Positive and Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer (HR+/HER2– mBC) and Triple-Negative Metastatic Breast Cancer (mTNBC)

   Current Oncology · 2026 DOI ↗
4. 2026

   Incidental Carcinomas and Lesions with Uncertain Malignant Potential (B3) Discovered During Symmetrization Mammoplasty in Breast Cancer Patients—Retrospective Single-Center Experience

   Surgeries · 2026 DOI ↗
5. 2025

   The Prognostic and Predictive Value of Body Mass Index in Patients with HR+/HER2− Breast Cancer Treated with CDK4/6 Inhibitors: A Systematic Literature Review

   Cancers · 2025 DOI ↗
6. 2025

   Recurrence Patterns in Breast Cancer: A Single-Center Retrospective Analysis

   Journal of Clinical Medicine · 2025 DOI ↗
7. 2025

   Real-World, National Study of Palbociclib in HR+/HER2− Metastatic Breast Cancer: A 2.5-Year Follow-Up PALBO01/2021

   Diagnostics · 2025 DOI ↗
8. 2025

   Risk factors for breast cancer recurrence in postmenopausal women: a bibliometric study

   Frontiers in Oncology · 2025 DOI ↗
9. 2023

   Perception of disease, dyadic coping, and the quality of life of oncology patients in the active treatment phase and their life partners: an approach based on the actor-partner interdependence model

   Frontiers in Psychology · 2023 DOI ↗
10. 2023

    Abstract P3-02-05: Interim Analysis Results from a European Disease Registry Study Aimed to Prospectively Observe Treatment Patterns and Outcomes in Patients with HER2+ Unresectable Locally Advanced or Metastatic Breast Cancer

    Cancer Research · 2023 · rezumat de conferință (SABCS) DOI ↗
11. 2023

    Pregnancy in a Young Patient with Metastatic HER2-Positive Breast Cancer—Between Fear of Recurrence and Desire to Procreate

    Current Oncology · 2023 DOI ↗
12. 2022

    Attitudes towards COVID‑19 vaccination in patients with cancer: A cross‑sectional study of 12 oncology centers

    Molecular and Clinical Oncology · 2022 DOI ↗
13. 2022

    Spectrum of BRCA1/2 Mutations in Romanian Breast and Ovarian Cancer Patients

    International Journal of Environmental Research and Public Health · 2022 DOI ↗
14. 2022

    Management of HER2-Positive Breast Cancer for a Young Patient with Visceral Crisis—The Adjuvant Role of Lifestyle Changes

    Current Oncology · 2022 DOI ↗
15. 2021

    The Pattern of Second Primary Tumours in Postmenopausal Women with Prior Breast Cancer in Western Romania: A Retrospective, Single-Institution Study

    Diagnostics · 2021 DOI ↗
16. 2021

    Well-Being, Depression, and Anxiety following Oncoplastic Breast Conserving Surgery versus Modified Radical Mastectomy Followed by Late Breast Reconstruction

    International Journal of Environmental Research and Public Health · 2021 DOI ↗
17. 2021

    Carcinomatous‑like mastitis due to axillary lymphadenopathy in a case of nasopharyngeal carcinoma: A case report

    Experimental and Therapeutic Medicine · 2021 DOI ↗
18. 2021

    Updated Overall Survival Analysis From IMpower110: Atezolizumab Versus Platinum-Based Chemotherapy in Treatment-Naive Programmed Death-Ligand 1–Selected NSCLC

    Journal of Thoracic Oncology · 2021 DOI ↗
19. 2021

    Comparative hematological profiles for dose‑dense vs. regular anthracycline‑based neoadjuvant chemotherapy in non‑metastatic breast cancer

    Experimental and Therapeutic Medicine · 2021 DOI ↗
20. 2021

    Unilateral Orbital Metastasis as the Unique Symptom in the Onset of Breast Cancer in a Postmenopausal Woman: Case Report and Review of the Literature

    Diagnostics · 2021 DOI ↗
21. 2021

    Skin-Reducing Mastectomy and Immediate Reconstruction for a Large Recurrent Borderline Phyllodes Tumor

    Applied Sciences · 2021 DOI ↗
22. 2020

    Endurance of erythrocyte series in chemotherapy

    Experimental and Therapeutic Medicine · 2020 DOI ↗
23. 2020

    Postmenopausal Breast Cancer in Women, Clinical and Epidemiological Factors Related to the Molecular Subtype: A Retrospective Cohort Study in a Single Institution for 13 Years. Follow-Up Data

    International Journal of Environmental Research and Public Health · 2020 DOI ↗
24. 2020

    Determining factors of renal dysfunction during cisplatin chemotherapy

    Experimental and Therapeutic Medicine · 2020 DOI ↗
25. 2020

    Veliparib with carboplatin and paclitaxel in BRCA-mutated advanced breast cancer (BROCADE3): a randomised, double-blind, placebo-controlled, phase 3 trial

    The Lancet Oncology · 2020 DOI ↗
26. 2020

    Patient-reported outcomes (PROs) in the randomized, phase III IMpower110 study of atezolizumab (atezo) vs chemotherapy in 1L metastatic NSCLC.

    Journal of Clinical Oncology · 2020 · rezumat de conferință DOI ↗
27. 2020

    The influence of cognitive schemas on the mixed anxiety-depressive symptoms of breast cancer patients

    BMC Women's Health · 2020 DOI ↗
28. 2019

    Phase III study of veliparib with carboplatin and paclitaxel in HER2-negative advanced/metastatic gBRCA-associated breast cancer

    Annals of Oncology · 2019 · rezumat de conferință (ESMO, LBA9) DOI ↗
29. 2018

    Efficacy and safety of CetuGEX in recurrent/metastatic squamous cell carcinoma of the head and neck (RM-HNSCC): results from the randomized phase II RESGEX study

    Journal of Clinical Oncology · vol. 36, supl. 5, p. 59 · 2018 · rezumat de conferință
30. 2017

    Safety and tolerability of subcutaneous trastuzumab for the adjuvant treatment of human epidermal growth factor receptor 2-positive early breast cancer: SafeHer phase III study's primary analysis of 2573 patients

    European Journal of Cancer · 2017 DOI ↗
31. 2017

    Effectiveness and safety profile of ipilimumab therapy in previously treated patients with unresectable or metastatic melanoma — the Romanian Patient Access Program

    Journal of B.U.ON. · 23(5), 1287–1295 · 2017
32. 2016

    NEPA, a fixed oral combination of netupitant and palonosetron, improves control of chemotherapy-induced nausea and vomiting over multiple cycles of chemotherapy: results of a randomized, double-blind, phase 3 trial versus oral palonosetron

    Supportive Care in Cancer · 2016
33. 2016

    Randomized Phase II Study of Duligotuzumab (MEHD7945A) vs Cetuximab in Squamous Cell Carcinoma of the Head and Neck (MEHGAN Study)

    Frontiers in Oncology · vol. 6, art. 232 · 2016
34. 2014

    The benefit of Faslodex administration in metastatic breast cancer — case presentation

    Oncologia Azi · nr. 5 · 2014
35. 2014

    Randomized phase II study of MEHD7945A vs cetuximab in ≥1 line recurrent/metastatic squamous cell carcinoma of the head and neck progressing on or after platinum-based chemotherapy

    Annals of Oncology · vol. 25, supl. 4, abs. 9860 · 2014 · rezumat de conferință
36. 2014

    A randomized phase III study evaluating the efficacy and safety of NEPA, a fixed dose combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy

    Annals of Oncology · vol. 25(7) · 2014
37. 2013

    No evidence of increased cyclophosphamide toxicity associated with the antiemetic agent NEPA, a fixed dose combination of netupitant and palonosetron

    55th ASH Annual Meeting, New Orleans · abs. 2949 · 2013 · poster
38. 2012

    DORINTA — the support group for breast cancer patients

    MASCC International Symposium, New York · Supportive Care in Cancer, 20 supl. 1, S44 · 2012 · poster
39. 2011

    Principles of Medical Oncology

    capitol în volumul „General Oncology” · Editura Victor Babeș, Timișoara · 2011
40. 2007

    CELER: an international randomized phase III trial of the CESAR Group — should chemotherapy be added to hormonal therapy in advanced breast cancer?

    The Breast · vol. 16, supl. 1 · 2007
41. 2006

    The Impact of Psychological Interventions on Breast Cancer Patients. A Romanian Pilot Study

    Psycho-Oncology · vol. 15, supl. 2, S422–423 · 2006
42. 2006

    Results of a patient information campaign using printed material

    Annals of Oncology · vol. 17, supl. 9, ix281 · 2006
43. 2005

    Oncomed — an oncology unit in Romania

    Improving Cancer Services Conference, Milano · 2005 · poster
44. 2004

    Lung cancer in the elderly

    capitol în volumul „Lung diseases in the elderly” · 2004
45. 2003

    Clinical Oncology

    capitol în volumul „Psycho-Oncology” · Editura Mirton, Timișoara · 2003
46. 2002

    The results of psychotherapeutic interventions in patients with cancer

    Conferința Națională de Psihiatrie, Timișoara · 2002 · comunicare orală
47. 2001

    Management of febrile neutropenia after chemotherapy

    Conferința Națională de Oncologie, București · 2001 · comunicare
48. 2001

    Acanthosis nigricans — paraneoplastic syndrome in a patient with non-small cell lung cancer

    Conferința Societății Române de Radioterapie, Oradea · 2001 · prezentare de caz